Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment

LAUR Repository

Show simple item record

dc.contributor.author Karaoui, Lamis R.
dc.contributor.author Tawil, Samah
dc.contributor.author Salameh, Pascale
dc.contributor.author Chamoun, Nibal
dc.date.accessioned 2019-11-15T08:05:11Z
dc.date.available 2019-11-15T08:05:11Z
dc.date.copyright 2019 en_US
dc.date.issued 2019-11-15
dc.identifier.issn 1473-2300 en_US
dc.identifier.uri http://hdl.handle.net/10725/11514
dc.description.abstract Objective This study was performed to evaluate the efficacy of daily subcutaneous enoxaparin 20 mg in patients with renal failure. Methods This retrospective cohort study included nonsurgical patients aged ≥18 years with a creatinine clearance rate of <30 mL/minute who were prescribed enoxaparin 20 mg subcutaneously (SC) daily for ≥3 days. The main outcome measures were the occurrence of a venous thromboembolic event (VTE) and bleeding events. Results One hundred sixty patients were identified. VTE occurred in 9 patients (5.6%), and bleeding events occurred in 37 (23.1%). Multivariable analysis showed that an age of >75 years was significantly associated with an increased risk of bleeding, while a creatinine clearance rate of 15 to 29 mL/minute was significantly associated with a lower risk of bleeding. Conclusion In patients with renal failure, enoxaparin 20 mg SC daily resulted in a 5.6% incidence of VTE, which is similar to the previously published acceptable incidence of VTE in patients with normal renal function receiving enoxaparin 40 mg SC daily. The incidence of major bleeding events was 10%, which is lower than that previously published in the literature. en_US
dc.language.iso en en_US
dc.title Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200101817 en_US
dc.author.idnumber 200201071 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of International Medical Research en_US
dc.journal.volume 47 en_US
dc.journal.issue 1 en_US
dc.article.pages 225-234 en_US
dc.keywords Enoxaparin en_US
dc.keywords Renal failure en_US
dc.keywords Thromboprophylaxis en_US
dc.keywords Bleeding en_US
dc.keywords Thrombosis en_US
dc.keywords Venous thromboembolism en_US
dc.identifier.doi https://doi.org/10.1177/0300060518799896 en_US
dc.identifier.ctation Karaoui, L. R., Tawil, S., Salameh, P., & Chamoun, N. (2019). Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment. Journal of International Medical Research, 47(1), 225-234. en_US
dc.author.email lamis.karaoui@lau.edu.lb en_US
dc.author.email nibal.chamoun@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://journals.sagepub.com/doi/full/10.1177/0300060518799896 en_US
dc.orcid.id https://orcid.org/0000-0002-7857-7374 en_US
dc.orcid.id https://orcid.org/0000-0002-0987-296X en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account